Memokath (Engineers & Doctors A/S, Hornbaek, Denmark) a second genera tion urethral stent composed of titanium nickel alloy with shape memory effect was deployed in 10 male spinal cord injured patients with urinary retention. The stent was inserted under sterile conditions via a delivery catheter under fluoroscopic control in seven and with the aid of a flexible cystoscope in three. The proximal end of the stent was positioned at the bladder neck and 50 ml of normal saline at 45°C was flushed through the stent which resulted in expansion of the distal most four coils of the stent in the proximal bulbar urethra; thus the internal sphincter (bladder neck) and external sphincter zone were kept open by the stent. Urethral stenting helped to achieve complete vesical emptying in all 10 patients. The complications included transient autonomic dysreflexia in two, transient urinary retention due to blood clot in one, and acute urinary tract infection in one patient. With a follow up of 3-7 months, all 10 patients have been aysmptomatic, with residual urine of less than 50 ml. There has been no migration or blocking of the stent. However, these stents require replacement at 12-18 months, but it is a short procedure as the Memokath, when cooled with saline at 4°C, becomes supersoft, enabling its easy and nontraumatic removal. As these stents produce no permanent effect upon the lower urinary tract and their removal is quick, safe and atraumatic, we prefer the second generation nickel titanium alloy stent to transurethral resection of bladder neck, external urethral sphincterotomy or permanent indwelling epithelialising stent, particu larly in young spinal cord injured patients who wish to retain their fertility potential.
Introduction
The concept of stenting the urethral sphincter in spinal cord injured patients, although it may appear to be a novel idea, is certainly not unique to medicine. As early as 1969, stents were being investigated in the peripheral arterial system as a means of preventing recurrent stenosis after dilation by balloon angioplasty.1 Since then, numer ous reports have demonstrated the effect iveness of stents in the renal, iliac, femoral, popliteal and coronary arterial systems. Stents also have been used in the gastro intestinal tract to maintain patency of sten otic ducts in the biliary tree. In the lower urinary tract, the initial experience with a permanently indwelling endoprosthesis has been in the bulbar urethra. In 1988, Milroy et al2 reported their preliminary results with eight patients in whom a permanent epithe lialising stent was used to treat difficult, recurrent bulbar urethral stricture. With regard to the management of detrusor ex ternal sphincter dyssynergia, in 1990 Shaw et al3 described nine patients with complete quadriplegia and detrusor external sphincter dyssynergia who were managed with the UroLume (AMS-Europe, Staines, UK) endoprosthesis instead of an external sphincterotomy. With the follow up ranging from 12 weeks to 12 months, eight patients (89%) had marked improvement in bladder emptying and the mean post-void residual urine decreased from 260 ml before stent insertion to 92 ml.
Chancellor et at in 19934 reported the results of a multicentre trial in North America with the UroLume wallstent as an alternative treatment for detrusor external sphincter dyssynergia. For the 119 patients in this investigation, the mean intravesical voiding pressure decreased from 77.7 + 26.2 cm water before the endoprosthesis was placed to 26.1 + 13.4 cm water at 12 months (p < 0.01). During the same period, the post-void residual urine volume de creased from 189 + 129 ml before insertion to 112 + 129 ml (p < 0.01). Stent migration occurred in five patients (4.2%), necessi tating removal of the endoprosthesis. How ever, no other untoward effects were noted. Memokath is a second generation stent composed of titanium nickel alloy with shape memory effect. The spiral can be inserted under sterile conditions via a de livery catheter. When flushed with hot water (45°C or above) the distal most section of the spiral expands and maintains the spiral in the proximal bulbar urethra. When cooled with cold water (10 °C or below), the spiral becomes supersoft, mak ing removal easy. We herein describe our preliminary experience with the use of Memokath in spinal cord injured patients for relief of bladder outlet obstruction.
Patients and methods
Male spinal cord injured patients with urin ary retention due to detrusor-sphincter dys synergia were the subjects of this study. The exclusion criteria were as follows. (1) Pa tients who were attending the fertility clinic and were undergoing electroejaculation or who were scheduled for electroejaculation in the near future. (2) Patients with sympto matic urinary tract infection. (3) Patients who were living far away from the centre and who did not have transport of their own. (This exclusion criterion was chosen because of our anxiety that, should there be any problem due to blocking of the stent or migration of the stent, these patients after stent deployment should be able to reach this centre within 2 hours for management of stent related problems.) (4) Presence of a vesical calculus. This was not an absolute contraindication and one patient with co existing vesical calculus underwent electro hydraulic lithotripsy of vesical calculus fol lowed by stent deployment 5 months later.
The merits and demerits of urethral stenting vis a vis other options that are currently available for treatment of detru sor-sphincter dyssynergia, e.g. division of external urethral sphincter, were discussed with the patient and the procedure of stenting was explained to him. If he agreed to undergo this procedure, he was scheduled for urethral stenting. Intravenous antibiotic (gentamicin 80 mg) was administered half an hour prior to the procedure. Temazepam 20 mg was given by mouth 1 hour prior to the procedure. The bladder was filled with 100 ml of urographic contrast through the Rusch (Rusch UK Ltd, High Wycombe, UK) 14 Fr ruler catheter with which subse quently the distance between the bladder neck and verumontanum was measured. (A stent 10 mm longer than the measured distance was chosen for deployment.) Con trast in the bladder also helped to delineate the bladder neck region for positioning the stent. Care should be taken to avoid disten sion of the bladder as it will precipitate an episode of autonomic dysreflexia. 10 mg of phentolamine was given intravenously and the stent-deploying catheter was inserted under fluoroscopic control. The proximal end of the stent was positioned in the bladder neck region. When the stent posi tioning was satisfactory, 50 ml normal saline at 45°C was injected through the main channel of the insertion catheter which resulted in expansion of the distal coils of the stent. The stent-retaining balloon situ ated beyond the proximal end of the stent was deflated and the insertion catheter was removed leaving the stent in place. Stenting was performed under fluoroscopic control in seven and in three others the stent was placed under vision with the aid of a flexible cystoscope. With the latter method of stent insertion, the distance from the bladder neck to the external sphincter zone was initially measured and a stent of appropriate length was chosen. The proximal end of the stent was positioned at the bladder neck and then 50 ml of the normal saline at 45°C was injected through the side port which re sulted in expansion of the distal coils of the stent. Thereafter, the cystoscope was with drawn and it could be verified that the stent traversed the sphincter zone. The distal end of the stent should be in the proximal bulbar urethra.
The patient was observed for 2-3 hours for (1) urethral bleeding; (2) febrile reac tion; (3) autonomic dysreflexia; and (4) retention of urine. When there was no complication, the patient was allowed to go home and was advised to take oral anti biotics (usually ciprofloxacin 500 mg twice a day for 5 days). He was reviewed after a week and then after a month, on which occasions a urine sample was taken for culture and abdominal ultrasound scan of urinary bladder was performed for measure ment of residual urine. Transrectal ultra sound was performed to check the position of the stent, i.e. relationship of proximal end of the stent to the bladder neck.
Results
The clinical profile of the 10 patients who underwent urethral stenting is given in Table I . Satisfactory deployment of the stent was achieved in all 10 patients. All the patients could void urine immediately after stent placement (Fig 1) . No patient devel oped profuse urethral bleeding or haema turia. Patients 4 and 5 developed features of autonomic dysreflexia immediately after stent placement. Ultrasound scan of the bladder revealed less than 50 ml urine, thus ruling out bladder distension as the aetio logical agent for the dysreflexic episode. Both the patients had only a mild degree of haematuria. It was presumed that the dys reflexic episode was due to the foreign body in the urethra. They were prescribed nifedi pine 10 mg whenever the systolic blood pressure rose to more than 160 mm Hg. Within 48 hours, the autonomic dysreflexic episodes subsided and have not recurred so far.
A tetraplegic (patient 7) underwent an uneventful stenting procedure in the after noon and was discharged home in the evening. However, he developed retention Paraplegia 32 (1994) 480-488 of urine 8 hours later and was admitted in the hospital. A 12 Fr silicone Foley catheter could be passed easily through the stent into the bladder and 400 ml urine was drained along with a few blood clots. The catheter was removed 24 hours later and he has been voiding well and asymptomatic since then. It is presumed that the blood clots blocked the stent leading to urinary retention.
One patient (3) was admitted 2 weeks later with acute urinary tract infection. He was prescribed cefotaxime 1 g intra venously, 8 hourly for 5 days. Abdominal and transrectal ultrasound scans revealed residual urine of less than 50 ml and proper positioning of the stent with no evidence of stent migration or encrustation over the stent. He has remained well since then. During follow up, no other patient devel oped symptomatic urinary tract infection. Post-void residual urine has been less than 50 m!. There has been no stent migration as revealed by transrectal ultrasonography.
Discussion
McInerney et als stated that the urethral stent when positioned over the external urethral sphincter zone holds the sphincter mechanism so wide open that global detru sor hypertrophy results in the subsequent bladder neck obstruction. Persistent res idual urine after transurethral external sphincterotomy has been attributed to blad der neck (internal sphincter) dyssynergia.6 Steers6 argued that one limitation of stenting the external urethral sphincter alone is the failure to correct obstruction at the internal sphincter or the creation of proximal obstruction. In many of our pa tients, attempted voiding cystourethrogram showed a closed bladder neck. Hence we preferred to stent both the internal sphincter and the external urethral sphincter. Permanently opening the bladder neck through a self-expanding prosthesis has been recommended as a useful adjunct in the treatment of sphincterotomy patients who have failed the initial procedure. 7 Stenting of the proximal urethra right from the bladder neck to and beyond the external sphincter helped to achieve com plete vesical emptying and to get rid of the indwelling urethral catheter in these pa tients. But urethral stenting in spinal cord injured patients poses some peculiar prob lems which are not encountered in able bodied individuals who undergo prostatic urethral stenting. During transfers (from the bed to the wheelchair etc) there can be minor but significant direct trauma to the perineum which may contribute to proximal migration of the stent. Such an eventuality is never encountered in healthy adult males undergoing prostatic stenting for benign hyperplasia of prostate or urethral stenting for stricture urethra. Similarly, manual evacuation of hard scybali may contribute to 'migration' of the stent in the spinal cord injured patient. This never occurs in the able bodied. The advantage of Memokath is that should migration of the stent occur, it can be easily repositioned with cystoscope and grasping forceps. It is not possible to manipulate the 'instent' as it tends to get deformed. In case one decides to remove the Memokath, the irrigating fluid for cysto scopy can be changed to normal saline at 4°C (10 °C or below) when the spiral be comes supersoft. When the grasping forceps engage the lower coil and it is pulled gently, the Memokath is transformed into a soft long wire and retraction is easily performed. The soft wire is unlikely to damage the mucous membrane of the urethra. Poulsen et als encountered bullous oedema in the urethral mucous membrane in four of the 30 consecutive patients with prostatic outflow obstruction in whom Memokath was inserted for relief of outlet obstruction. These authors concluded that, although titanium nickel shape memory alloy is known to be highly biocompatible, a local reaction to this material in the urethral lining could not be excluded. They suggest that as per the consensus at the Inter national Academy of Shape Memory Mater ial for Medical Use in 1992, the titanium nickel alloy should not be used in patients with nickel allergy.
Chancellor et al9 deployed the prosthesis in such a manner that the proximal location of the stent was halfway on the verumon tanum and the distal end of the stent was in the bulbar urethra, at least 5 mm beyond the end of the external sphincter. Chancellor et al9 successfully carried out electroejacula tion after such a placement of a Urolume endourethral wallstent prosthesis, with re covery of motile sperm evident at semen analysis in a spinal cord injured patient. McInerney et al5 suggested that for patients requiring fertility investigation and treat ment, the stent should be placed distal to the verumontanum so that the stent does not obstruct the ejaculatory ducts. We were concerned about the possible effect of electroejaculation upon the urethra after placement of a titanium nickel prosthesis. Hence, as of today, we do not recommend this stent in patients who are likely to undergo electroejaculation for their fertility programme. Alternatively, the Memokath could be removed just prior to electroejacu lation and then a new stent can be inserted at the end of electroejaculation under the same anaesthesia.
The current literature on urethral stenting in spinal cord injured patients has been Tables II and III. Oester ling,13 who recently reported the long term results of the North American clinical trial on the Urolume endoprosthesis as a treat ment for recurrent bulbar urethral stric tures, stated that a permanently indwelling endoprosthesis may be a valuable alternat ive to external sphincterotomy for the treat ment of detrusor external sphincter dys synergia. If stents are introduced into an environment that has microorganisms (e.g. urinary tract), bacteria will colonise the surface irreversibly, precluding any form of tissue incorporation. The adaptive mechan isms of bacteria by which they attach per manently to the surface of prostheses are well recognised 14 and explain the inability of eukaryotic cells to compete effectively for the colonisation of the surfaces. This is probably why stents do not get incorporated in tubular structures lined by mucosal tissue. Despite the apparent coverage of the stent surface by mucosal growth at endoscopy, histologic examination shows proliferation through the metal interstices. IS Although some of these polypoid growths coalesce over the metal, the stent is not truly incorporated in the wall thickness because mucosal cells are still present on the ablu minal side of the stent. 16 Recently a bio resorbable urethral stent has been investi gated in rabbits by Kemppainen et al. 17 The bioresorbable urethral stent is made of biodegradable self-reinforced poly-L-lactide to achieve an active initial tissue reaction and better tissue penetration. As the tissue reaction around the bioresorbable stent material is minimal, the chances of stenosis due to exuberant fibrotic proliferation re quiring endoscopic treatment which has been reported with the self-expandable urethral stent (wallstent) may be diminished in case of the bioresorbable stent. Thus the controversy remains as to whether we should use a permanent epithelialising endoprosthesis, or a bioresorbable urethral stent or a stent which can be removed easily such as the Memokath in spinal cord injured patients. Recently, the intravascular stents are being coated to diminish the thrombo genic properties. Similarly, coating can be made to the urethral stents to prevent bacterial colonisation and encrustations.
Stent coatings can be classified as biological or prosthetic; the latter can be subdivided into passive coating and active coating. Active coatings include several new mater ials that can incorporate drugs such as low molecular weight heparin released slowly for sustained local action. Biological coating is represented by seeding of endothelial cells over the stent surface before deployment. Dichek et al18 reported successful seeding of endothelial cells genetically engineered by recombinant DNA techniques to produce tissue plasminogen activation over the stents. The search for the ideal urethral stent is continuing and devices made of superior design and material will hopefully be made available soon for spinal cord injured patients. However, more studies with a large number of patients and extended follow up will be necessary to confirm initial findings, determine the durability of the stents and assess late complications in spinal cord injured patients whose chances of survival have much im proved because of the global care being provided by specialised spinal injury cen tres. As of today, the permanent epithelial ising endoprosthesis and the second genera tion temperature-sensitive Memokath stent composed of titanium nickel alloy with shape memory effect are the main contend ers for deployment in the spinal cord injured patient. We believe that each stent has its own indications and they are not competi tors, but complement each other in provid ing individualised care. For example, in a 20 year old tetraplegic with detrusor-sphincter dyssynergia, who is not yet married, and for whom preserving his fertility is one of the main considerations, division of the external sphincter is completely ruled out. We prefer to insert a Memokath in this patient so that when he plans his family, the Memokath can be easily removed and he can safely undergo an electroejaculation schedule. However, in a 60 year old tetraplegic patient with sphinc terotomy failure, and who has completed his family, a permanently indwelling epithelial ising endoprosthesis is a one time procedure and the risks of a possible obstruction of the ejaculatory ducts are of minor concern and can be ignored. In contrast, the Memokath stent will require replacement at least once in 12-24 months. It has been stated that the epithelialising stents can be removed trans urethrally at any time if necessary; irrespect ive of the stent design, the overlying epithe lium can be resected using a low cutting current, and the stent is then freed from its bed and removed through a protective instrument, such as a resectoscope sheath. Current experience on removal of the epi thelialising stents and consequences of such removal on the urethra and the ejaculatory duct orifices is very limited and we would be sceptical in making any assurance to our patients regarding the safety of such a
